Study identifier:D0810C00022
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Open Label, Dual Centre Study To Assess The Safety And Tolerability Of AZD2281 In Combination With Bevacizumab (Avastin®) In Patients With Advanced Solid Tumours
Neoplasm Metastasis
Phase 1
No
AZD2281, Bevacizumab
All
18
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
Phase I, open label, dual centre, dose finding study to evaluate the safety and tolerability of continuous twice daily oral dosing with AZD2281 when administered in combination with Bevacizumab 10mg/kg given every 2 weeks to patients with advanced solid tumours.
Location
Location
Manchester, United Kingdom
Location
Oxford, United Kingdom
Arms | Assigned Interventions |
---|---|
Experimental: 1 Dose Escalation Study 50, 100, 200, 400 mg | Drug: AZD2281 Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing Other Name: Olaparib Drug: Bevacizumab IV administration10 mg/kg every 14 days Other Name: Avastin |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.